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In spinal muscular atrophy (SMA), the leading genetic cause of early childhood death, the survival motor
neuron 1 gene (SMN1) is deleted or inactivated. The nearly identical SMN2 gene has a silent mutation that
impairs the utilization of exon 7 and the production of functional protein. It has been hypothesized that thera-
pies boosting SMN2 exon 7 inclusion might prevent or cure SMA. Exon 7 inclusion can be stimulated in cell
culture by oligonucleotides or intracellularly expressed RNAs, but evidence for an in vivo improvement of
SMA symptoms is lacking. Here, we unambiguously confirm the above hypothesis by showing that a bifunc-
tional U7 snRNA that stimulates exon 7 inclusion, when introduced by germline transgenesis, can efficiently
complement the most severe mouse SMA model. These results are significant for the development of a
somatic SMA therapy, but may also provide new means to study pathophysiological aspects of this devastat-
ing disease.
INTRODUCTION
The hypothesis that boosting the inclusion of exon 7 in the
SMN2 gene might provide an effective treatment or cure for
SMA is based on the fact that all SMA patients have at least
one, often several, SMN2 copies (1,2). This copy number
inversely correlates with the severity of the disease (3,4).
However, there also appear to be modulating effects from
other genes or of non-genetic origins (5–7).
Exon 7 of the SMN2 gene is arguably one of the best studied
exons of the human genome. It appears to be weak, as it is
skipped, albeit infrequently, even in the functional SMN1
gene. This weakness is due to a suboptimal intron 6 branch
point (8), a non-canonical 50 splice site (ss), intronic splicing
silencers (ISS) in both flanking introns and an inhibitory
secondary structure towards the end of the exon (9). Positive
elements are two exonic splicing enhancers (ESEs), termed
SE1 and SE2, which contain binding sites for the splicing
factors ASF/SF2 and hTra2b, respectively. In the SMN2
gene, a silent mutation appears to weaken SE1 (10,11) and
may cause the formation of an additional hnRNP A1-dependent
silencing element (12,13).
A stimulation of exon 7 inclusion has been achieved in cell
culture models with antisense oligonucleotides that target
either of the two ISS, the inhibitory sequences towards the
end of exon 7, or, alternatively, mask the intron 7 branch
point and 30 ss of exon 8 (9,14,15). In one of these studies, oli-
gonucleotides were also introduced into a SMA mouse model,
and splicing correction could be detected in liver and kidney.
However, the oligonucleotides did not reach the spinal cord,
and hence no therapeutic benefit could be demonstrated (15).
Moreover, an elevation of SMN protein could recently be
demonstrated after intracerebral injection of an oligonucleo-
tide (16). Two studies, published in 2003, were using bifunc-
tional oligonucleotides targeting the part of exon 7 that differs
between SMN1 and SMN2 and additionally containing either
an ESE sequence (17) or a peptide composed of alternating
serines and arginines mimicking a SR protein (18). We have
recently adapted several of these oligonucleotide-based
approaches to an U7 snRNA-derived in vivo expression
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cassette. Additionally, we have tried to improve exon 7
inclusion by using modified U1 and U2 snRNAs targeting
the 50 ss and the intron 6 branch point, respectively (8,19).
As a conclusion from these studies, we arrived at an optimal
exon 7 inclusion strategy based on a bifunctional U7 construct
(termed U7-ESE-B; Fig. 1A) which targets the 30 part of exon
7 and carries an ESE sequence that can attract stimulatory spli-
cing factors (19). This construct induced a nearly complete
exon 7 inclusion of a SMN2-luciferase reporter in HeLa
cells as well as of the endogenous SMN2 gene in SMA type
I patient fibroblasts. In these fibroblasts, we also saw a 2- to
3-fold increase in SMN protein and, concomitantly, an
increase of SMN-containing nuclear gems to a frequency
also seen in certain wild-type cells or very mild forms of
SMA (20). In the present study, we have introduced this
U7-ESE-B cassette by transgenesis into the most severe
SMA mouse model. We observe a clear suppression of
disease-associated symptoms which can, in the most efficient
cases, allow a normal weight development, muscle perform-
ance and life expectancy. These results fully confirm that
exon 7 is the target of choice for SMA therapies, although
future studies will have to show whether a correction starting
after birth can still be beneficial. In addition, the transgenic
approach in SMA mouse models should also be helpful for
further investigations into SMA pathophysiology.
RESULTS
Therapeutic benefit of U7-ESE-B in a severe SMA model
We used the U7-ESE-B construct in a transgenic approach to
test the hypothesis that the stimulation of SMN2 exon 7
inclusion could alleviate SMA symptoms. U7-ESE-B trans-
genic mice were generated by lentiviral vector (LV)-mediated
transgenesis (21). Two founder mice were chosen, based on
cytofluorometric analyses of blood samples for the intensity
of the green fluorescent protein (GFP) contained in the LV
(Fig. 1B), and crossed with carriers of a mouse SMA model
(described below). The mean fluorescence intensities and the
numbers of integrated LV copies (determined by quantitative
real-time polymerase chain reaction (PCR) of Gag and wood-
chuck hepatitis virus posttranscriptional regulatory element
(WPRE) sequences) of these and further animals described
below are documented in Supplementary Material, Table S1.
In the chosen SMA model, the most severe of its kind, the
breeders are heterozygous for mouse smn (smnþ/2) and
homozygous for human SMN2 (hSMN2þ/þ) and therefore
have a similar genotype as human SMA carriers (22). The
SMA-affected pups emerging from these breedings
(smn2/2; hSMN2þ/þ) have an average lifespan of 5.2+
0.2 days (23). In their terminal stage, they have the weight
and appearance of 2–3-day-old normal pups.
When crossing the U7-ESE-B transgenic mice with SMA
breeders, we found that both founder animals transmitted the
GFP and U7 genes through the germline. GFP mean fluor-
escence intensities and integrated gene copy numbers
decreased, on average, by a factor of 2 for each generation
(Supplementary Material, Table S1), which suggested that
the multiple integrations were not clustered. In successive
crossings of the first generation offspring with SMA breeders,
we obtained mice with the desired genotype: smn2/2;
hSMN2þ/þ; U7-ESE-Bþ (variable copy numbers); these
will henceforth be called SMA/U7 animals. For 15 of these
SMA/U7 animals, a survival curve was established (Fig. 2).
Copy numbers of the LV carrying the U7-ESE-B cassette
varied between 1 and 12.5 in these animals (median 1.7).
Six of these animals were censored (three for removal of
tissues on day 32, one having died of an unrelated cause on
day 275 and two mice remaining alive beyond 300 days).
The other SMA/U7 animals died or were euthanized because
of severe SMA symptoms between days 18 and 290. The
median survival time was 123 days. In comparison, SMA
mice (11 animals, seven censored because they were eutha-
nized on days 3 or 4 based on genotyping) had a median sur-
vival time of 6.5 days. This is comparable with the average
lifespan reported for such mice (23) (see above). Most impor-
tantly, the 20-fold increase in survival times of SMA/U7
compared with U7 mice is highly significant (P , 0.0001).
Two litters from U7-ESE-B bearing mothers with 15 and
seven LV copies per diploid genome which had eight and
nine pups, respectively, were compared in more detail for
their weight development during the first 2 months and for
their muscle performance. Each of these litters consisted of
three SMA/U7 pups, three smnþ/þ pups (termed wild-type)
and two or three smnþ/2 pups (termed heterozygous),
respectively (see Supplementary Material, Table S1 for more
complete genotype description). Weights, general appearance,
Figure 1. Structure of U7-ESE-B snRNA-containing LV used for mouse trans-
genesis. (A) The U7-ESE-B splicing correction cassette contains an antisense
sequence directed to the 30 part of human SMN2 gene exon 7 and an additional
splicing enhancer sequence (19). The modified U7 moiety is represented by its
30 terminal stem loop and its Sm protein core (pictured as a grey ball). Within
exon 7, the C to U transition that distinguishes SMN1 and SMN2 and that is
thought to disrupt an ESE, the central ESE (SE2) and the UAA stop codon
are indicated with white letters. (B) Structure of the LV pRRL-SIN-
cPPT-hPGK-GFP-WPRE (32). The U7-ESE-B cassette is inserted upstream
of the human phosphoglycerate kinase promoter in sense orientation with
respect to the GFP open reading frame. Typical for a third generation
vector, the 50 LTR contains U3 sequences from Rous sarcoma substituting
for those of HIV-1 (RSV-RU5). The 30 LTR carries a self-inactivating (SIN)
deletion. WPRE, woodchuck hepatitis virus post-transcriptional regulatory
element; cPPT, HIV-1 central polypurine tract; C, HIV-1 packaging signal.
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motility and additional disease-associated symptoms were
initially recorded twice daily and later at wider intervals.
Fig. 3 shows the weight development of these animals for
the first 60 days after birth.
The three SMA/U7 pups (568, 573 and 575) born from
mother 523 with the higher U7-ESE-B copy number had a
nearly normal weight development, compared with their litter-
mates (Fig. 3A). They contained between five and 12 LV
insertions in their genomes (Supplementary Material,
Table S1; Fig. 3C). They never showed any SMA-related
disease symptoms (one of them died of an ear infection on
day 275). One of these female SMA/U7 animals, 575, was
bred with a wild-type male to see if it was able to carry,
deliver and feed pups normally. Out of this coupling, seven
pups were born which all developed normally beyond the
time of weaning. These findings clearly show that the
U7-ESE-B cassette can improve and sometimes even fully
suppress the severe SMA symptoms.
In the litter of mother 558 with the lower U7-ESE-B copy
number, two SMA/U7 pups showed a growth retardation
after days 3–5 and their weight began to decrease at days
13 and 17, respectively (Fig. 3B). Based on criteria established
in agreement with the animal experimentation authorities,
these mice were euthanized on days 18 and 20, respectively.
The other SMA/U7 pup from the same litter (580) had a
reduced weight development and performed very weakly in
a grid holding test (see below). It also displayed necrosis of
the tail and of two toes on each hind foot. However, the necro-
sis stopped after some time, and the skin healed at these sites
(Supplementary Material, Fig. S1). Such symptoms have been
described previously for milder SMA mouse models (24).
Importantly, mouse 580 did not display severe general
disease symptoms, was always moving and eating well, until
it died on day 290, apparently of a sudden SMA progression.
Grid holding tests (see Materials and Methods) performed on
days 35, 42 and 56 after birth indicated that the SMA/U7 animal
580 displaying disease symptoms was able to hold suspended on
the grid for 6–30 s in the first, for 1–4 s in the second and not at
all in the third test series (Fig. 4A, column 7). The symptom-free
SMA/U7 animals 573 and 575 showed a completely normal
holding time (columns 3 and 4). Only animal 568 had a
reduced holding time in all tests (column 2), but seemed to
improve with each new series (not shown). Note that a
reduced performance was also observed in all three series for
one of the heterozygous animals (581, data not shown but
included in the wt/hz values; column 1). Thus, a reduced
holding time may sometimes reflect an unwillingness to collab-
orate rather than a muscle weakness. Importantly, when the data
of the three SMA/U7 animals from this litter were pooled, the
median corresponded to the maximal length of the measure-
ments, 120 s (column 5).
The SMA/U7 animals 568, 573 and 575 and their wild-type
and heterozygous littermates were subjected to Rotarod
running tests on days 88 and 105–107 after birth (summarized
in Fig. 4B). It is evident from the graph that the SMA/U7
Figure 2. The presence of the U7-ESE-B cassette prolongs survival in SMA
mice. SMA mice (turquoise) are homozygous for an insertional inactivation of
the smn gene and homozygous for a human SMN2 transgene (22). SMA/U7
mice (purple) additionally contain between one and 12 copies (median 1.7) of a
LV carrying the U7-ESE-B cassette Dashed lines indicate 95% confidence inter-
vals. n, number of mice reaching endpoint (death or euthanasis due to severe SMA
symptoms) or being censored, separated by a slash. Times when animals were
censored are shown as upward blips. Reasons for censoring were: SMA, euthana-
sis after positive genotyping; SMA/U7, removal of tissues on day 32 (three
animals), death of an unrelated cause (ear infection) on day 275 (one) and survival
beyond the reporting period (two). The difference between the median survival
times—123 days for SMA/U7, 6.5 for SMA—is highly significant (P, 0.0001).
Figure 3. Weight development of SMA mice containing the U7-ESE-B cas-
sette. Two female mice (smn+; hSMN2+; containing multiple copies of
U7-ESE-B) were bred with SMA carrier males and the weight of their pups
was measured at frequent intervals. (A) Mouse 523 (30 copies of
U7-ESE-B per diploid genome) had three SMA/U7 pups with two hSMN2
copies, three wild-type and two heterozygous pups. (B) Mouse 558 (seven
copies of U7-ESE-B) had three SMA/U7 pups with two hSMN2 copies,
three wild-type and two heterozygous pups. The SMA/U7 pups 558-1-4 and
558-1-5 had to be euthanized on days 18 and 20, respectively. (C) Numbers
of U7-ESE-B LV copies inserted in the genome of the above SMA/U7
mice. The real-time PCR indicated 0.5 copies in mouse 558-1-4, but non-
quantitative PCR indicated that it contained at least one transgene copy.
Animal identification: three digit numbers represent ear tag numbers intro-
duced at weaning age. Animals killed at an earlier age are identified by the
ID of their mother, the litter and a numbering system for animals of the
same litter, based on foot tattooing on the day of birth (for example,
558-1-4 is pup 4 from the first litter of mother 558).
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animal 573 performed considerably more weakly than the
other two SMA/U7 animals and most of the wild-type or
heterozygous mice from the same litter. However, the wild-
type animal 572 also had a strongly reduced performance.
The performances of the SMA/U7 animals 568 and 575
were only slightly reduced compared with those of the other
wild-type or heterozygous littermates.
Taken together, these results demonstrate that a phenotypic
improvement is observable in all SMA/U7 animals, but that it
is variable, ranging from a short increase in life span to a
virtually full suppression of all symptoms (e.g. in the SMA/
U7 mouse 575).
Molecular and histological characterization
of SMA/U7 mice
To determine how efficiently the U7-ESE-B snRNA corrects
hSMN2 splicing, we analysed total spinal cord RNA by
reverse transcription (RT)-PCR. As the primers were not
complementary to mouse smn; RT-PCR bands were only
obtained from mice containing the human SMN2 gene, but
not from smn þ/þ mice lacking the human gene or from
the mouse neuroblastoma cell line NB2A (Fig. 5A). To
analyse the splicing correction, we used spinal cord RNA
from 6-day-old wild-type, heterozygous and SMA mice with
various numbers of integrated U7-ESE-B vector copies and
from a 3-day-old SMA mouse lacking U7-ESE-B. As
expected, in the spinal cord of the SMA mouse lacking a
U7-ESE-B insert, only a small proportion of hSMN2 mRNA
contained exon 7 (26%; Fig. 5B). In contrast, all the mice
containing the U7-ESE-B vector—wild-type, heterozygotes
and SMA/U7—had an improved hSMN2 exon 7 inclusion.
Although there was no strict correlation, mice with higher
U7-ESE-B copy numbers generally showed a stronger splicing
correction. An improvement of exon 7 inclusion was also
observed in RNA samples from other tissues (data not shown).
We then analysed the level of SMN protein in spinal cord
extracts by western blotting (Fig. 6). All analysed animals
Figure 4. Muscle performance of SMA mice containing the U7-ESE-B cas-
sette. (A) On days 35, 42 and 56, the ability of the remaining mice from
litters 523-1 and 558-1 to hang suspended under a metal grid for up to
120 s was measured (three tests per day and mouse). n, number of individual
test values. (B) On days 88 and 105–107, the mice from litter 523-1 were
tested for their ability to run for up to 240 s on a Rotarod running device
with the rotation speed increasing linearly from 10 to 40 rpm (six tests per
day and mouse, 24 values in total). The boxes (grey for SMA/U7 mice,
white for wild-type or heterozygous animals) encompass all values in the
10–90 percentile range. A thick horizontal bar indicates the median.
Because of the maximum cut-off time, the values do not fall into a normal
(Gaussian) distribution.
Figure 5. Increased SMN2 exon 7 inclusion in SMA mice containing the
U7-ESE-B cassette. (A) Gel with controls showing that the RT-PCR assay
detects transcripts of human SMN2, but not mouse smn. NB2A, RNA from
mouse neuroblastoma cell line NB2A; nohSMN2, RNA from spinal cord of a
mouse that does not contain the human SMN2 gene; the last three lanes corre-
spond to the identically labelled lanes in (B); 2RT, identical reaction as for the
wt mouse, but with reverse transcriptase omitted; M, 100 bp size marker. The
picture is a negative photograph of an ethidium bromide-stained agarose gel.
The RT-PCR bands correspond to full-length SMN2 mRNA (FL) and RNA
lacking exon 7 (Dex7). (B) RT-PCRs carried out with total spinal cord RNA
from various mice. Note that all animals in the black labelled lanes (including
wild-type [wt] and heterozygous [hz] ones) contain the U7-ESE-B cassette and
hence show a splicing correction compared with the SMA mouse (red labelled
lane). The numbers of integrated U7-ESE-B vector copies, as determined by
quantitative PCR, are indicated above the lanes. The picture shows a denaturing
polyacrylamide gel of reactions carried out in the presence of 32P-labelled
dCTP. The per cent inclusion values were averaged from well correlating
values of this gel scan and of a capillary electrophoretic analysis of an
RT-PCR carried out with a fluorescently labelled downstream primer (see
Materials and Methods). All samples were obtained at post-natal day 6,
except for the SMA sample which was from a 3-day-old animal. M, size
marker (end-labelled HpaII digest of pBR322).
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were 3 days old, and different amounts of extract were loaded
on the gel to facilitate a semi-quantitative assessment. Accord-
ingly, high levels of SMN were detected in wild-type (Fig. 6)
and heterozygous animals (data not shown), which expressed
mouse smn and hSMN2 that was partly corrected. For the
SMA mouse that expressed only uncorrected hSMN2, the
intensity of the SMN band in 10 mg of total protein was
fainter than that seen in 1.25 mg of wild-type extract. Thus it
appears to contain less than one-tenth the amount of SMN in
its spinal cord than a wild-type mouse. In contrast, the
SMA/U7 mouse contained approximately one-fifth of the
amount of SMN of the wild-type mouse but clearly more
than the SMA animal without U7-ESE-B cassette. Similar
results were obtained with other mice (data not shown). In
conclusion, the presence of the U7-ESE-B allows for a clear
but moderate increase in SMN protein level in the spinal cord.
To assess the preservation of motoneurons, 31-day-old
animals from a single litter composed of three wild-type, het-
erozygous and SMA/U7 animals each were analysed. Spinal
cord cross-sections sampled to reflect most of the body axis
were stained with Toluidine blue (Fig. 7A). The number of
large neuronal cells per ventral horn (considered to be moto-
neurons) showed a broad variation (data not shown). Since
the sampling covered most of the length of the spinal cords
and similar numbers of ventral horn sections (50–61) were
counted in all animals, average values were used for compari-
son. This quantitative analysis revealed no significant differ-
ence between SMA/U7 animals and their wild-type and
heterozygous littermates (Fig. 7B). We also isolated and
stained spinal cords from 3-day-old SMA animals. However,
although motoneurons were clearly visible (Fig. 7A), in our
hands a reliable quantitative analysis was not possible due to
the relatively poor tissue preservation and small size. It has
been reported, though, that affected mice surviving up to
day 5 show a loss of 35% of motor neurons in the spinal
cord and 40% in the facial nucleus (22).
Although the western blot analysis had indicated a partial
restoration of SMN protein expression in the spinal cord, it
was important to know whether this was also true at the
level of motoneurons. We therefore stained spinal cord
sections from the same animals used for the histological
analysis with anti-SMN antibody and used a 40,6-diamidino-
2-phenylindole (DAPI) counterstain to identify cell nuclei.
Neuronal nuclei can be distinguished from those of other
(mostly glial) cells based on their larger size and patchier
DAPI staining (Fig. 7C). The cytoplasm of motoneurons from
heterozygous (Fig. 7C, top row) and wild-type animals (not
shown) gets intensely stained for SMN, but the nuclear space
remains void of staining except for occasional gems. In the
SMA animal (middle row), the cytoplasm of motoneurons
showed virtually no staining. Staining of motoneurons was
clearly recovered in spinal cord sections from SMA/U7
animals (bottom row), although it was weaker than in hetero-
zygous or wild-type animals. The staining appeared to be some-
what more granular, but it is possible that a higher density of the
same granules might suggest a more even distribution in the
heterozygous or wild-type animals. Importantly, however,
the staining also extended into axonal processes. Thus, these
analyses show that SMN production is partly restored in SMA/
U7 animals, not only at the total spinal cord level, but also
within the motoneurons, the cells primarily affected in SMA.
DISCUSSION
This study unambiguously and fully validates the hypothesis
that SMA symptoms may be reduced or even completely sup-
pressed by treatments that improve the utilization of SMN2
exon 7. The range of phenotypic improvement seen in the
SMA/U7 mice analysed here goes from short life prolongation
or normal life span with pronounced SMA symptoms to full
weight development, muscular function and the ability of a
female to carry to term and feed a normal sized litter of pups.
Most of these animals contained one to seven copies of the
U7-ESE-B transgene (except for one animal having 12
copies). There was no strict correlation between the number
of integrated U7-ESE-B copies and the phenotype of the
SMA/U7 pups, but animals with higher copy numbers
tended to show fewer and less severe symptoms. Exon 7
inclusion in total spinal cord RNA was increased from 26 to
52%, and SMN protein levels were also increased, albeit
only to an estimated one-fifth of the levels seen in wild-type
or heterozygous animals. That such a small increase in SMN
levels may have a significant impact on viability, and SMA
symptoms are in agreement with the findings of Gavrilina
et al. (25) who showed that low SMN cDNA expression in
spinal cord can substantially prolong survival.
The fact that we saw only partial correction of SMN2
splicing and low levels of SMN production could be traced
to a very weak expression of the U7-ESE-B transgene that
was hardly detectable by primer extension (Supplementary
Material, Fig. S2). We have recently made the striking obser-
vation that different mouse U7 gene derivatives that we use for
splicing correction are highly expressed in human, but poorly
in mouse, cells (J.M. unpublished data). The reasons for this
phenomenon are still under investigation, but this means that
a higher expression might be expected in human patients, so
that a single U7-ESE-B transgene per cell might be sufficient
for a phenotypic correction. We are also investigating ways to
improve the expression to achieve this goal.
These findings raise hopes for a therapy for SMA. As all
patients carry at least one copy of SMN2, they may all
Figure 6. Increased SMN protein levels in SMA mice containing the
U7-ESE-B cassette. Western blot detecting SMN and b-actin (loading
control). The samples used were spinal cord lysates from 3-day-old animals
520-4-9 (wt; 2.5 U7-ESE-B copies; see Supplementary Material, Table S1),
608-2-1 (SMA) and 520-4-2 (SMA/U7; 5.3 U7-ESE-B copies). The amounts
of protein loaded on the gel are indicated below the lanes. The anti-SMN anti-
body detects both human and mouse SMN. H, HeLa protein extract loaded as
marker.
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benefit from a treatment able to improve exon 7 inclusion,
particularly in motoneurons. However, there is still a long
way to go, and it is presently unclear which type of
therapy—small drugs, oligonucleotides or the type of thera-
peutic gene used here—will be first and most successful.
Viewing its efficiency, our small U7-ESE-B gene is a good
candidate, but its efficient and safe delivery to motoneurons
will have to be established. Primary, but not exclusive,
options are AAV vectors (26–28), but the serotype, strain
and application routes must yet be elaborated.
Besides its importance in opening perspectives for SMA
therapy, the transgenic approach that we have chosen also
offers distinct possibilities to increase our knowledge
about SMA in the mouse model. We have recently developed
a doxycycline-inducible system for the regulation of therapeutic
U7 cassettes (29). We now plan to introduce this system into
SMA mice by transgenesis in order to address important ques-
tions, such as when during ontogenesis low levels of SMN are
particularly critical, whether there is a point of no return after
which a therapy can no longer rescue the motoneurons from
dying, or whether the disease will still develop if a correction
of SMN2 splicing is discontinued after the first phases of post-
natal life. Additionally, mice can now be derived with stable
single-copy insertions that should show intermediate SMA phe-
notypes due to partial SMN2 splicing correction. These could be
used to decipher molecular events occurring in the affected
motoneurons, e.g. through the use of splicing microarrays.
This is particularly important, because recent studies suggest
Figure 7. Preservation of motoneurons and SMN protein localization in SMA mice containing the U7-ESE-B cassette. (A) Toluidine blue staining of spinal cord
cross-sections of the indicated mice. Mice 635 hz (heterozygote for smn), 638 wt (wild-type for smn) and 642 SMA/U7 were all from the same litter and 31 days
of age; the SMA mouse 503-3-4 (from a separate litter) was 3 days old. (B) Counts of large neurons in spinal cord ventral horns of all nine animals (634–642)
from the same litter. Five to seven sections from five different spinal cord areas separated about 5 mm from each other were used to count large neuronal cells in
at least 50 ventral horns per animal. The average values from each animal were calculated, and the mean and standard deviation are shown for each group of
animals (three animals per group). For the three SMA/U7 animals, the numbers of integrated U7-ESE-B vector copies as determined by quantitative PCR were
between 1.2 and 1.9 (see Supplementary Material, Table S1). (C) Immunofluorescence analysis of SMN protein in spinal cord sections. The panels show over-
views (left) and close-ups (right) with SMN immunofluorescence in red (single confocal planes) and DAPI staining of nuclei in blue (stack overlays). Samples
shown are from heterozygous (hz) and SMA/U7 animals and from the 3-day-old SMA pup also used in (A). Staining patterns of wild-type animals were very
similar to the ones shown for the heterozygous mouse. For the SMA animal, the areas occupied by some of the motoneuron nuclei are indicated by white inter-
rupted lines to illustrate that the surrounding cytoplasmic area shows virtually no SMN staining. The red background staining comes from the secondary antibody
which primarily binds to blood capillaries; in contrast no spill over was observed between the DAPI staining and the red channel.
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that the distribution of spliceosomal snRNPs and the splicing of
many genes are deranged in a tissue-dependent manner,
suggesting that SMA may be primarily a disease caused by
splicing changes (30,31).
MATERIALS AND METHODS
Molecular cloning and LV transgenesis
The previously described U7-ESE-B splicing correction cas-
sette (19) was amplified by PCR with the primers
U7-5end-XhoI and U7-3end-EcoRV with Pfu-Ultra polymer-
ase (Stratagene, La Jolla, CA, USA) according to the manufac-
turer’s recommendations. For primer sequences see
Supplementary Material, Table S2. The XhoI/EcoRV fragment
was then transferred into the third generation LV
pRRL-SIN-cPPT-hPGK-GFP-WPRE (32), between the cPPT
and the hPGK promoter, in forward orientation with regard
to eGFP. The entire U7 cassette and surrounding elements
were verified by sequencing.
LVs were produced as described (33) except that super-
natant was harvested twice (at 24 and 36 h post-transfection)
and that serum-free Episerf medium (Gibco Invitrogen,
Basel, Switzerland) was used instead of DMEM with fetal
calf serum. LV transgenesis was carried out as described (21).
Animal strains, breeding and husbandry
The SMA mouse strain (22) was obtained from Jackson Labora-
tory (strain name: FVB.Cg-Tg(SMN2)89Ahmb smn1tm1Msd/J,
Stock number: 005024). These mice are heterozygous for a
LacZ-Neo insertion in exon 2 of their smn gene and additionally
carry two copies of the human SMN2 transgene. Crosses
between these animals result in progeny that are homozygous
for the smn mutation and carry two copies of the SMN2 trans-
gene. Such animals have been reported to die between 4 and 7
days after birth (22,23). In contrast, homozygous smn knock-out
mice without the SMN2 transgene show embryonic lethality with
an arrest in development before the stage of implantation (34).
The U7 transgene was inserted by LV-based transgenesis
into oocytes of B6d2F2 mice (work performed in the labora-
tory of D. Trono at the EPFL, Lausanne, Switzerland) (21).
Female transgenic animals were then crossed with SMA
carrier males. A second cross with SMA carriers yielded
mice of the desired genotype [smn2/2; hSMN2þ/þ;
U7-ESE-Bþ (multiple copies)], which are termed SMA/U7.
All mice were kept in individually ventilated cages in the
animal facility of the Insel hospital in Berne, Switzerland in
compliance with in compliance with legal requirements for
animal husbandry and with the specific authorization issued
for this project by the cantonal animal protection authority.
In particular, litters with expected SMA genotypes were
initially looked after twice daily and weighed once a day.
Some older mice no longer used for experiments were
moved to a conventional animal facility.
Cytofluorometric GFP detection in blood samples
Approximately 50 ml tail vein blood was mixed with 1 ml
phosphate-buffered saline (PBS) containing 5 mM EDTA and
centrifuged for 5 min at 500g and 48C. The pellet was
gently resuspended in 4 ml of red blood cell lysis buffer
(150 mM NH4Cl, 10 mM KHCO3 and 0.1 mM EDTA) and incu-
bated for 10 min at room temperature in the dark. Cells were
precipitated by centrifugation as above, and the red super-
natant containing destroyed red blood cells was removed.
Remaining cells were resuspended in 1 ml PBS, and GFP
expression was measured by cytofluorometry (FACS
Calibur, BD Bioscience, Meyrin, Switzerland). Age-matched
blood not expressing GFP was used to define a negative popu-
lation. The geometric mean of fluorescence intensity was
determined with the FlowJo software version 7.2.4.
Genotyping
Genomic DNA was isolated from tail biopsies, usually taken on
the day of birth, by using the Wizard genomic DNA purification
Kit (Promega AG, Wallisellen, Switzerland). For the PCRs, 20 ml
of reactants containing 50–200 ng genomic DNA, 400 nM of the
corresponding primers (see Supplementary Material Table S2),
200 mM of each deoxyribonucleotide triphosphate, 4 ml of
Q-solution and 1 U of Taq Polymerase (Qiagen AG, Hombrech-
tikon, Switzerland) were incubated for 30 s at 948C, 1 min at
508C and 2 min at 728C for 40 cycles.
For the smn genotype, one common forward primer (mSmn
Fw) and two reverse primers (mSmn Re and Neo border) were
used. Intact and mutated smn yield products of 594 and
1200 bp, respectively. In heterozygous animals, both bands are
produced. To determine the SMN2 copy number, a common
forward primer (Tg89-Grm7-Fw) was used, again together
with two distinct reverse primers (Tg89-Grm7-Neg and Tg89-
SMN-Re) (25). Thus, in heterozygous animals, two products of
280 and 372 bp were observed, representing the alleles with
and without integration of SMN2, respectively. A qualitative
assay for LV integration made use of the primer pWPTS-
Sequencing and GFP10b and yielded an amplicon of 1406 bp
in the positive case. For gender determination, the primers sry
30 and sry 50 yielded a male-specific product of 600 bp. For
primer sequences see Supplementary Material, Table S2.
Real-time PCR
Starting from 70 ng of mouse genomic DNA, we amplified
Gag and WPRE sequences in the lentiviral construct, and
Titin, a mouse housekeeping gene (35) (see Supplementary
Material, Table S2 for primers and probes). The absolute
amount of each gene was determined by referring to a standard
curve. This consisted of a 10-fold serial dilution of a plasmid
containing one copy of each of the genes, with known copy
numbers at each dilution (six concentrations ranging from
106 to 10 copies for each gene). The absolute copy number
of transgene integrated in the genome was obtained by divid-
ing the amount of each reporter gene, Gag or WPRE, by half
of the Titin amount, since the plasmid contains a single copy
of the Titin gene, whereas the genomic DNA contains two
copies. Values calculated with the Gag and WPRE assays
correlated with a correlation coefficient R2 ¼ 0.9547, but
WPRE-derived values were on average 20% higher. As it is
not possible to say which assay is more correct, all values
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presented in Supplementary Material, Table S1 and in the
main manuscript are averages between the two determinations.
The real-time PCRs were run in simplex with the ABI Prism
7000 sodium dodecyl sulphate (SDS) v1.1 system (Applied
Biosystem, Foster City, CA, USA). Mice genomic DNA or
serial dilutions of the plasmid were included in a mix contain-
ing 2 Absolute QPCR Rox mix buffer (Thermo Scientific,
Waltham, MA, USA), 162 nM of specific primers, 800 nM of
corresponding TaqMan probe and water to a 18 ml final
volume. The run conditions were as follow: 9600 emulation
mode, one 15 min 958C polymerase activation step, followed
by 40 cycles of two-step qPCR (15 s of 958C denaturation,
1 min of 608C combined annealing/extension).
Muscle performance tests
Grid holding test. Mice were placed on a grid and allowed to
get a firm hold. Then the grid was turned upside down for
2 min, and the time for which the animals were able to hang
on to the grid was measured. Three such tests were performed
during each session, whereby the animals were allowed to
recover for 1 min between the measurements. These tests
were carried out three times with 1 week intervals.
Rotarod assay. This assay was carried out in the animal facility
of the University of Fribourg, Switzerland with the kind support
and advices from J. Schwaller and P. Gregory. After initial train-
ing sessions on a RotaRod device (TSE Systems GmbH, Bad
Homburg, Germany), the mice were tested with a protocol
applying accelerating speed of 10–40 rpm for up to 4 min.
Each mouse did six trials per day, three in the morning and
three in the afternoon; the break between the individual trials
was at least 10 min, and the break between morning and after-
noon was 3 h. The time that the animals were able to keep
running was recorded. The data were analysed by using the
Prismw software (GraphPad, San Diego, USA).
RNA analysis
Total RNA was extracted with homemade Tri-Reagent (29)
and resuspended in diethyl pyrocarbonate-treated water.
Two micrograms of total RNA were reverse-transcribed into
first-strand cDNA, by using 200 nM of oligo-dT, 50 U of
Stratascript 6.0 reverse transcriptase (Stratagene), 1 Strata
6.0 buffer (Stratagene), 500 mM of all four dNTPs (Roche
Diagnostics AG, Rotkreuz, Switzerland), 10 mM DTT and
8 U RNAsin (Promega) in a total volume of 50 ml.
PCRs including radioactive label were carried out with Taq
DNA polymerase (Qiagen) in a volume of 25 ml with 5 ml of
cDNA, 200 nM each of the SMN-Ex6-Fw (200 nM) and SMN-
Ex8-Re primers, a mix containing 200 mM of dATP, dTTP and
dGTP and 20 mM dCTP, 5 mCi a-32P-dCTP (Hartmann Analytic
GmbH, Braunschweig, Germany). Cycling conditions were 45 s
at 958C, 1 min at 508C and 1 min at 728C for 27 cycles. The PCR
products were separated by electrophoresis on a 6% denaturing
polyacrylamide gel. After exposure to phosphor storage
screens (Molecular Dynamics, Sunnyvale, CA, USA), the
intensity of radioactivity in the bands lacking (130 bp) or con-
taining (184 bp) SMN2 exon 7 was estimated with the AIDA
software (version 2.31, Raytest Isotopenmessgera¨te GmbH,
Straubenhardt, Germany) and values were corrected by normali-
zing them for the number of Cs in the molecule. In one experi-
ment, the PCR was carried out in the absence of radioactive
dCTP, but the forward primer was 50 end-labelled with 6-
carboxyfluorescein (CF). The PCR product (1.2 ml) was mixed
with 12 ml of GS500 LIZ standard (12.5 ml diluted in 1 ml of
Hi-Di formamide, Applied Biosystems) and run for fragment
analysis on an ABI 3100 sequencer (Applied Biosystems). The
relative amounts of the products lacking or containing SMN2
exon 7 were estimated from the areas of the corresponding
peaks. The percentage of inclusion was calculated as the value
of the included band divided by the sum of both products.
The two methods yielded very similar results and the results
were therefore averaged for inclusion in Fig. 5 of the paper.
For primer extension, 10 pmol of Pex-U7-Universal (detect-
ing U7-ESE-B) or Pex-U2-WT (detecting endogenous U2
snRNA) primers were 50 labelled with 10 U of T4 polynucleo-
tide kinase (New England Biolabs, Ipswich, MA, USA) in the
presence of 20 pmol of g-32P-ATP (Hartmann Analytic), and
the labelled primers were used without further purification.
Five micrograms of total RNA were slowly hybridized in a
thermocycler with a mix of 100 fmol of both primers, and
the RT reaction was performed as described above, except
that the incubation was extended for 2 h. The products were
separated on 15% denaturing polyacrylamide gels and the
signals were analysed as described (19).
Western blot
A polyclonal anti-SMN antibody was produced by immunizing
New Zealand white rabbits with a recombinant protein corre-
sponding to the first 180 amino acids of mouse SMN. Antibodies
were affinity-purified with the recombinant protein used for
immunization. Bound antibodies were eluted with 0.2 M
glycine, pH 2.8, neutralized and stored at 48C.
For western blots, tissue samples were lysed in RIPA buffer
(137 mM NaCl, 10 mM phosphate, 2.7 mM KCl, 0.1% SDS,
0.5% sodium desoxycholate and 1% Igepal CA-630) sup-
plemented with proteinase inhibitors (Complete EDTA-free,
Roche). Extracts were resolved on 10% high-TEMED SDS–
polyacrylamide gels and proteins were transferred onto
reinforced nitrocellulose membranes (0.45 mm, Schleicher
and Schuell, Bottmingen, Switzerland). SMN was detected
with a 1:500 dilution of affinity-purified rabbit anti-mSMN
antibody in TBS–tween–milk (Tris-buffered saline: 20 mM
Tris-HCl, pH 7.5, 135 mM NaCl; supplied with 0.1% Tween
20 and 5% fat-free milk powder), while actin was detected
by using a 1:500 dilution of the anti-actin (20–33) antibody
(Sigma-Aldrich Chemie GmbH, Buchs SG, Switzerland) in
TBS–tween–milk. The primary antibodies were then detected
with a species-specific antibody coupled to horseradish peroxi-
dase (Promega), and signals were visualized by the enhanced
chemiluminescence method (Amersham Biosciences) and
digitalized with the Luminescent Image Analyser LAS-1000
plus (Fujifilm AG, Dielsdorf, Switzerland).
Histology and immunofluorescence
Spinal cord sectioning, staining and neuron counting. At post-
natal day P31, spinal cords from the littermates 634–642 were
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isolated and cut close to the cervical end. From there on, five
pieces of 5 mm length were embedded in M-1 Embedding
Matrix for frozen sectioning (six fluid OZ, Thermo Shandon,
Pittsburgh) and kept frozen at 2208C until use. From each
5 mm part, 10–12 cryosections of 25 mm were cut with a
Leitz 1720 Cryostat/Microtome (Leica Microsystems GmbH,
Wetzlar, Germany), floating in PBS and then transferred to
TBS containing 0.1% Triton X-100 from where they were
taken onto microscope slides (superfrost, Menzel-Gla¨ser,
Braunschweig, Germany) and left to dry at least 5 h or over
night. Then the slides were fixed in 100% ethanol for
10 min and transferred to the toluidine blue staining solution
(1.2 g toluidine blue O and 3 g Na2CO3 dissolved in 360 ml
doubly distilled H2O, 40 ml of 70% ethanol and 400 mg
NaN3) for 6.5 min. Then, the slides were washed twice
shortly in 70% ethanol and incubated for 1 min in 100%
ethanol before putting them shortly in 100% xylol from
where they were taken for embedding in Eukitt.
Before counting, the slides were blinded and assigned
random numbers. All slides were then counted by a single
person (that was not involved in the blinding) to minimize
differences in counting criteria. A virtual line was drawn at
the level of the central canal and all clearly visible large
cells anterior to this line were considered to be neurons and
counted. For each of the five regions of a spinal cord, at
least 10 anterior horns were counted.
Immunohistochemistry. Cryosections from 31-day-old litter-
mates 634 (WT), 635 (HZ) and 642 (SMA-U7), as well as
from the 3-day-old mouse 504-4-4 (SMA, without therapeutic
U7) were used. Floating sections were transferred from PBS
into TBS. Then, the slides were incubated with TBS containing
1% Triton X-100 for 30 min and washed 2 10 min with TBS
followed by a 2-day incubation at 48C with the monoclonal
anti-SMN antibody 2B1 (Sigma, 1:500 diluted in TBS contain-
ing 1% BSA and 0.1% NaN3). Then, the sections were washed
3  10 min in TBS before incubation with the secondary anti-
body goat-anti-mouse IgG conjugated to Alexa-594 (Invitrogen,
1:1000 diluted in TBS containing 1% BSA) for 2 h at room
temperature in the dark. After washing 3  10 min with TBS,
the samples were incubated with DAPI (Invitrogen, 5 ng/ml in
TBS containing 1% BSA) and washed again 3  10 min
before they were transferred to microscope slides and embedded
with Glycergel (Dako Inc., Carpinteria, CA, USA).
Preparations were analysed on an Eclipse 600 microscope
equipped with a DXM1200 camera (Nikon, Tokyo, Japan)
or on a Laser Scan Microscope SP2, (Leica Microsystems).
Image processing was performed with ImageJ 1.34s (National
Institutes of Health, Bethesda, MD, USA) and Corel Graphics
Suite software (Corel GmbH, Unterschleissheim, Germany).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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